Whether small molecules as potential ARDS-modulating modalities, such as with the nmMLCK peptide inhibitor PIK or biologic entities such as the eNAMPT-neutralizing ALT-100 mAb, the integrin β4-neutralizing mAb, the ANGPT2-neutralizing mAb, or the PSGL1-neutralizing biologic strategies, there has been profound progress in the development of ARDS relevant EC-targeted therapies. Here, ANGPT2 is linked to acute respiratory distress syndrome.